These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 26464261)

  • 21. Autonomic dysfunction and arterial stiffness in female overactive bladder patients and antimuscarinics related effects.
    Hsiao SM; Su TC; Chen CH; Chang TC; Lin HH
    Maturitas; 2014 Sep; 79(1):65-9. PubMed ID: 25022469
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
    Kaplan SA; Roehrborn CG; Rovner ES; Carlsson M; Bavendam T; Guan Z
    JAMA; 2006 Nov; 296(19):2319-28. PubMed ID: 17105794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment.
    Chou EC; Hung MJ; Yen TW; Chuang YC; Meng E; Huang ST; Kuo HC
    J Formos Med Assoc; 2014 Aug; 113(8):506-12. PubMed ID: 25037757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of Overactive Bladder Step Therapy Policies on Medication Utilization and Expenditures Among Treated Medicare Members.
    Abbass IM; Caplan EO; Ng DB; Kristy R; Schermer CR; Bradt P; Collins JM; Chan WM; Suehs BT
    J Manag Care Spec Pharm; 2017 Jan; 23(1):27-37. PubMed ID: 28025920
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome.
    Speakman M; Khullar V; Mundy A; Odeyemi I; Bolodeoku J
    Curr Med Res Opin; 2008 Aug; 24(8):2173-9. PubMed ID: 18565239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
    Chapple CR; Nazir J; Hakimi Z; Bowditch S; Fatoye F; Guelfucci F; Khemiri A; Siddiqui E; Wagg A
    Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms.
    Serels SR; Toglia MR; Forero-Schwanhaeuser S; He W
    Curr Med Res Opin; 2010 Oct; 26(10):2277-85. PubMed ID: 20707767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
    Warner JL
    BJU Int; 2010 Aug; 106(4):586. PubMed ID: 20653664
    [No Abstract]   [Full Text] [Related]  

  • 30. Solifenacin in the treatment of overactive bladder syndrome in Italian patients: pharmacoeconomic evaluation.
    Pradelli L; Iannazzo S
    J Med Econ; 2009 Mar; 12(1):25-35. PubMed ID: 19450062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic benefit in patients switching tolterodine to other novel antimuscarinic agents.
    Sánchez-Ballester F; Miranda P; Lizarraga I; Rejas J; Arumi D
    Actas Urol Esp; 2014 Apr; 38(3):156-63. PubMed ID: 24119382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER.
    Zinner N; Noe L; Rasouliyan L; Marshall T; Seifeldin R
    Curr Med Res Opin; 2008 Jun; 24(6):1583-91. PubMed ID: 18423103
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fesoterodine clinical efficacy and safety for the treatment of overactive bladder in relation to patient profiles: a systematic review.
    Chapple C; Oelke M; Kaplan SA; Scholfield D; Arumi D; Wagg AS
    Curr Med Res Opin; 2015 Jun; 31(6):1201-43. PubMed ID: 25798911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of solifenacin and fesoterodine in treatment of overactive bladder.
    Ercan Ö; Köstü B; Bakacak M; Aytaç-Tohma Y; Çoşkun B; Avcı F; Efe E
    Saudi Med J; 2015 Oct; 36(10):1181-5. PubMed ID: 26446328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tolterodine for the treatment of urge urinary incontinence.
    Elterman DS; Chughtai B; Kaplan SA; Barkin J
    Expert Opin Pharmacother; 2013 Oct; 14(14):1987-91. PubMed ID: 23885788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics.
    Wagg A; Nitti VW; Kelleher C; Castro-Diaz D; Siddiqui E; Berner T
    Curr Med Res Opin; 2016; 32(4):621-38. PubMed ID: 26828974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
    Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
    BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparing anticholinergic persistence and adherence profiles in overactive bladder patients based on gender, obesity, and major anticholinergic agents.
    Lua LL; Pathak P; Dandolu V
    Neurourol Urodyn; 2017 Nov; 36(8):2123-2131. PubMed ID: 28467609
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Comparisons of therapeutic efficacy and safety of solifenacin versus tolterodine in patients with overactive bladder: a meta-analysis of outcomes].
    Liu B; Li P; Li J; Wang Y; Wu Y
    Zhonghua Yi Xue Za Zhi; 2014 Aug; 94(30):2350-4. PubMed ID: 25399976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.